FSDDF - FSD Pharma Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.63
-0.06 (-9.35%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.69
Open0.69
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.61 - 0.70
52 Week Range0.07 - 0.88
Volume1,393,303
Avg. Volume789,962
Market Cap820.361M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.01
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • FSD Pharma and SciCann Therapeutics Launch Cardiovascular Research Program in Tel Aviv University
    CNW Group23 hours ago

    FSD Pharma and SciCann Therapeutics Launch Cardiovascular Research Program in Tel Aviv University

    TORONTO , Sept. 23, 2018  FSD Pharma Inc. ("FSD Pharma" or "FSD") (HUGE.CN) (FSDDF) (0K9.F) is pleased to announce the launch of a comprehensive sponsored research program in Tel Aviv University together with its strategic R&D partner, SciCann Therapeutics Inc. ("SciCann"), focused on the cardiovascular disease field. The new research program is aimed at the development of novel and proprietary cannabinoid-based treatments for the prevention and treatment of atherosclerosis, the underlying factor for most cases of stroke and cardiac stenosis events in the western world. Dr. Zohar Koren, Co-founder and CEO of SciCann stated, "The prevalence of Coronary Artery Disease (CAD) among adults in North America is estimated at 8% of the population and considered to be the number one killer disease in the western world.

  • FSD Pharma and SciCann Therapeutics Launch Cardiovascular Research Program in Tel Aviv University
    PR Newswire23 hours ago

    FSD Pharma and SciCann Therapeutics Launch Cardiovascular Research Program in Tel Aviv University

    TORONTO, Sept. 23, 2018  FSD Pharma Inc. ("FSD Pharma" or "FSD") (HUGE.CN) (FSDDF) (0K9.F) is pleased to announce the launch of a comprehensive sponsored research program in Tel Aviv University together with its strategic R&D partner, SciCann Therapeutics Inc. ("SciCann"), focused on the cardiovascular disease field. The new research program is aimed at the development of novel and proprietary cannabinoid-based treatments for the prevention and treatment of atherosclerosis, the underlying factor for most cases of stroke and cardiac stenosis events in the western world. Dr. Zohar Koren, Co-founder and CEO of SciCann stated, "The prevalence of Coronary Artery Disease (CAD) among adults in North America is estimated at 8% of the population and considered to be the number one killer disease in the western world.

  • ACCESSWIRE3 days ago

    Marijuana Stock Report For Friday September 21, 2018

    CORAL GABLES, FL / ACCESSWIRE / September 21, 2018 / Marijuana stocks have remained on a high during the month of September and pre market trading has a number of these cannabis stocks heading higher. Traders have flocked to medical-marijuana producers like Tilray (TLRY), for instance, after the company won approval from the Drug Enforcement Administration to import a cannabis product drug into the U.S. for a clinical trial. With this being the case, there are multiple cannabis companies to look at as the October date in Canada comes closer.

  • FSD Pharma Inc. Announces $7.5 Million Dollar at $1 Per Share Investment as Part of Existing Strategic Alliance with Auxly Cannabis Group Inc.
    CNW Group4 days ago

    FSD Pharma Inc. Announces $7.5 Million Dollar at $1 Per Share Investment as Part of Existing Strategic Alliance with Auxly Cannabis Group Inc.

    TORONTO , Sept. 20, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (HUGE.CN) is pleased to announce that pursuant to the approved construction and development budget announced on July 3, 2018 (Link), Auxly Cannabis Group Inc. (TSX.V – XLY) ("Auxly") has made an equity investment into the Company at $1.00 per Class B Subordinate Voting Share for total proceeds of $7.5 million . The buildout of the Joint Cultivation Footprint is currently underway in Cobourg, Ontario and will include dedicated space for large scale extraction capabilities. In addition to the Joint Cultivation Footprint, FSD is also implementing several technological advancements at the Cobourg facility aimed at increasing energy efficiency and post-harvest process automation.

  • FSD Pharma Announces Upgraded Listing to OTCQB Venture Market
    PR Newswire5 days ago

    FSD Pharma Announces Upgraded Listing to OTCQB Venture Market

    CSE: HUGE OTCQB: FSDDF FRA: 0K9 TORONTO , Sept. 19, 2018 /PRNewswire/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (CSE: HUGE) (FRA: 0K9) announced today that its subordinate voting ...

  • FSD Pharma Announces Upgraded Listing to OTCQB Venture Market
    CNW Group5 days ago

    FSD Pharma Announces Upgraded Listing to OTCQB Venture Market

    FSD Pharma Announces Upgraded Listing to OTCQB Venture Market

  • FSD Pharma signs collaboration and profit sharing agreement with Canntab for production and market of oral dose delivery platforms
    CNW Group6 days ago

    FSD Pharma signs collaboration and profit sharing agreement with Canntab for production and market of oral dose delivery platforms

    TORONTO , Sept.18, 2018 /CNW/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD Pharma" or the "Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that it has signed a definitive collaboration and profit sharing agreement (the "Agreement") with Canntab Therapeutics Limited (CSE:PILL) ("Canntab"), a leader in the rapidly growing cannabis pill market, effective September 17, 2018 . Under the terms of the Agreement, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the "License"), and will provide Canntab with space at its facility (the "FSD Facility"), which is located just one hour east of Toronto in Cobourg, Ontario (the "Transaction").

  • FSD Pharma signs collaboration and profit sharing agreement with Canntab for production and market of oral dose delivery platforms
    PR Newswire6 days ago

    FSD Pharma signs collaboration and profit sharing agreement with Canntab for production and market of oral dose delivery platforms

    TORONTO, Sept.18, 2018 /PRNewswire/ - FSD Pharma Inc. (HUGE.CN) (FSDDF) (0K9.F) ("FSD Pharma" or the "Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that it has signed a definitive collaboration and profit sharing agreement (the "Agreement") with Canntab Therapeutics Limited (CSE:PILL) ("Canntab"), a leader in the rapidly growing cannabis pill market, effective September 17, 2018. Under the terms of the Agreement, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the "License"), and will provide Canntab with space at its facility (the "FSD Facility"), which is located just one hour east of Toronto in Cobourg, Ontario (the "Transaction").

  • FSD Pharma joins Snipp's Cannabis Marketing Resource Center
    PR Newswire7 days ago

    FSD Pharma joins Snipp's Cannabis Marketing Resource Center

    CSE: HUGE OTC: FSDDF FRA: 0K9 TORONTO , Sept. 17, 2018 /PRNewswire/ - FSD Pharma Inc. ("FSD" or the "Company") (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) today announced that it has joined ...

  • FSD Pharma joins Snipp's Cannabis Marketing Resource Center
    CNW Group7 days ago

    FSD Pharma joins Snipp's Cannabis Marketing Resource Center

    FSD Pharma joins Snipp's Cannabis Marketing Resource Center

  • FSD Pharma to Expand into Jamaican Market and Introduce FSD Jamaica
    PR Newswire11 days ago

    FSD Pharma to Expand into Jamaican Market and Introduce FSD Jamaica

    TORONTO, Sept. 13, 2018 /PRNewswire/ - FSD Pharma Inc. ("FSD" or the "Company") (HUGE.CN) (FSDDF) (0K9.F) is pleased to announce that it intends to launch a strategic partnership into the Jamaican cannabis market as part of its plan to expand internationally. FSD has signed a Letter of Intent ("LOI") effective September 10, 2018 with JJAMACANN Inc. ("JJAMACANN") to form a joint venture operating as FSD Jamaica ("FSD Jamaica"). FSD Jamaica expects to partner locally with Nature's Purest Limited ("NPL"), a Jamaican corporation with a cultivation license and existing operations in Jamaica.

  • FSD Pharma to Expand into Jamaican Market and Introduce FSD Jamaica
    CNW Group11 days ago

    FSD Pharma to Expand into Jamaican Market and Introduce FSD Jamaica

    FSD Pharma to Expand into Jamaican Market and Introduce FSD Jamaica

  • FSD Pharma Breaks All-time Daily Volume Record and Continues to Make History
    CNW Group12 days ago

    FSD Pharma Breaks All-time Daily Volume Record and Continues to Make History

    TORONTO , Sept. 12, 2018 /CNW/ - FSD Pharma Inc. ("FSD" or the "Company") (HUGE.CN) (FSDDF) (0K9.F), is pleased to report that on September 11, 2018 the Company traded an aggregate total of exactly 213,761,823 shares. FSD traded 143,260,988 Class B subordinate voting shares on the Canadian Securities Exchange ("CSE"), 1,888,500 on AQC-Lit, 15,369,000 on AQC-Neo, 241,740 on CXC, 5,309,399 on CX2, 6,473,592 on CXD, 22,500 on Lynx, 24,750,500 on Omega and 16,445,604 on MatchNow. This is the largest total quantity of share volume traded by a CSE listed issuer by over 15.7% above the recorded all-time high of 184,718,114 also achieved by FSD on September 10, 2018 , as confirmed by the CSE.

  • FSD Pharma Issues 40,000,000 Stock Options to Director Dr. Raza Bokhari Conditional on NASDAQ listing
    PR Newswire13 days ago

    FSD Pharma Issues 40,000,000 Stock Options to Director Dr. Raza Bokhari Conditional on NASDAQ listing

    TORONTO, Sept. 11, 2018 /PRNewswire/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (HUGE.CN) (FSDDF) (0K9.F) announces that pursuant to its Stock Option Plan, the Board approved the grant of 3,000,000 stock options for class B subordinate voting shares of the Company (the "Options") on August 14, 2018 to Dr. Raza Bokhari following his appointment as a Director. The Board has also approved an additional grant of 40,000,000 Options to Dr. Bokhari exercisable at a price of $0.74 for a period of five years.

  • FSD Pharma Issues 40,000,000 Stock Options to Director Dr. Raza Bokhari Conditional on NASDAQ listing
    CNW Group13 days ago

    FSD Pharma Issues 40,000,000 Stock Options to Director Dr. Raza Bokhari Conditional on NASDAQ listing

    TORONTO , Sept. 11, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (HUGE.CN) (FSDDF) (0K9.F) announces that pursuant to its Stock Option Plan, the Board approved the grant of 3,000,000 stock options for class B subordinate voting shares of the Company (the "Options") on August 14, 2018 to Dr. Raza Bokhari following his appointment as a Director. The Board has also approved an additional grant of 40,000,000 Options to Dr. Bokhari exercisable at a price of $0.74 for a period of five years.

  • ACCESSWIRE14 days ago

    3 Biotech & Marijuana Stocks to Pay Attention to this Quarter

    GTBiopharma (GTBP), for instance has been building a biopharmaceutical pipeline targeting everything from pain management to cancer treatments. This therapy targets cancer cells expressing the CD19 receptor and/or CD22 receptors, which includes B-cell leukemias and lymphomas and has a modified form of diphtheria toxin (DT390) as its cytotoxic drug payload. After OXS-1550 binds to cancer cells, it is taken in by the cancer cells and subsequently deploys its cytotoxic diphtheria toxin payload, which inhibits protein synthesis and kills the cancer cells.

  • FSD Pharma Congratulates High Tide Ventures for Selection as Supplier to Ontario Cannabis Retail Corporation
    CNW Group17 days ago

    FSD Pharma Congratulates High Tide Ventures for Selection as Supplier to Ontario Cannabis Retail Corporation

    FSD Pharma Congratulates High Tide Ventures for Selection as Supplier to Ontario Cannabis Retail Corporation

  • FSD Pharma Congratulates High Tide Ventures for Selection as Supplier to Ontario Cannabis Retail Corporation
    PR Newswire17 days ago

    FSD Pharma Congratulates High Tide Ventures for Selection as Supplier to Ontario Cannabis Retail Corporation

    TORONTO, Sept. 7, 2018 /PRNewswire/ - FSD Pharma Inc. ("FSD Pharma" or "FSD") (HUGE.CN) (FSDDF) (0K9.F) today congratulated High Tide Ventures Inc. ("High Tide") for the selection of its wholly-owned subsidiary Famous Brandz Inc. ("Famous Brandz") as an accessories supplier to the Ontario Cannabis Retail Corporation, operating as the Ontario Cannabis Store ("OCS"). Under the announcement by the OCS on September 5, 2018, Famous Brandz was one of ten accessories suppliers newly-selected to supply accessories to the adult-use market in the Province of Ontario.

  • FSD Pharma breaks all-time daily volume record and makes history again
    CNW Group19 days ago

    FSD Pharma breaks all-time daily volume record and makes history again

    FSD Pharma breaks all-time daily volume record and makes history again

  • FSD Pharma breaks all-time daily volume record and makes history again
    PR Newswire19 days ago

    FSD Pharma breaks all-time daily volume record and makes history again

    TORONTO, Sept. 5, 2018 /PRNewswire/ - FSD Pharma Inc. ("FSD" or the "Company") (HUGE.CN) (FSDDF) (0K9.F), is pleased to report that on September 4, 2018 the Company traded an aggregate total of exactly 151,183,895 shares. FSD traded 106,397,927 Class B subordinate voting shares on the Canadian Securities Exchange ("CSE"), 5,883,500 on AQC-Lit, 5,180,500 on AQC-Neo, 501,526 on CXC, 751,300 on CX2, 8,781,217 on CXD, 382,000 on Lynx, 8,631,000 on Omega and 14,674,925 on MatchNow. This is the largest total quantity of share volume traded by a CSE listed issuer by over 33.6% above the recorded all-time high of 113,135,861 achieved by FSD on its first day of trading, as confirmed by the CSE.

  • FSD Pharma Reports Q2 Results
    PR Newswire24 days ago

    FSD Pharma Reports Q2 Results

    TORONTO, Aug. 30, 2018 /PRNewswire/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (HUGE.CN) (FSDDF) reported its financial and operational results for the second quarter of fiscal 2018, ended June 30th, 2018.   These filings are available for review on the Company's SEDAR profile at www.sedar.com. The Company maintained a strong balance sheet with cash of $31,700,000, no debt, significant assets and continues to execute on management's vision of becoming the largest indoor grow facility in the world with total grow capacity, once completed, in excess of 3,000,000 square feet.

  • FSD Pharma Reports Q2 Results
    CNW Group24 days ago

    FSD Pharma Reports Q2 Results

    TORONTO , Aug. 30, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (HUGE.CN) (FSDDF) reported its financial and operational results for the second quarter of fiscal 2018, ended June 30 th, 2018.   These filings are available for review on the Company's SEDAR profile at www.sedar.com. FSD Pharma continues to make Strategic early stage investments in the Cannabis industry with like minded companies that 1) provide excellent investment potential and 2) will assist FSD strategically in its business.  An example of this is evidenced by this quarters mark to market asset revaluation of FSD's holding in Cannara Biotech resulting in a $7,500,000 gain.

  • FSD Pharma reports positive pre-clinical results for proprietary CBD combination product
    CNW Grouplast month

    FSD Pharma reports positive pre-clinical results for proprietary CBD combination product

    TORONTO , Aug. 23, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or "FSD") (HUGE.CN) (FSDDF) (0K9.F) reports today that its strategic R&D partner, SciCann Therapeutics Inc. ("SciCann"), has achieved positive results in a pre-clinical efficacy study of its proprietary "Steady Stomach" CBD combination product for Inflammatory Bowel Disease (IBD).

  • FSD Pharma reports positive pre-clinical results for proprietary CBD combination product
    PR Newswirelast month

    FSD Pharma reports positive pre-clinical results for proprietary CBD combination product

    TORONTO, Aug. 23, 2018 /PRNewswire/ - FSD Pharma Inc. ("FSD Pharma" or "FSD") (HUGE.CN) (FSDDF) (0K9.F) reports today that its strategic R&D partner, SciCann Therapeutics Inc. ("SciCann"), has achieved positive results in a pre-clinical efficacy study of its proprietary "Steady Stomach" CBD combination product for Inflammatory Bowel Disease (IBD).

  • FSD Pharma Completes Harvest and Microbial Testing of First Lot
    PR Newswirelast month

    FSD Pharma Completes Harvest and Microbial Testing of First Lot

    TORONTO, Aug. 21, 2018 /PRNewswire/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (HUGE.CN) (FSDDF) (0K9.F) is pleased to announce that its wholly-owned subsidiary, FV Pharma Inc. ("FV Pharma"), a licensed cannabis producer under the Access to Cannabis for Medical Purposes Regulations (the "ACMPR"), completed the harvest of its first lot of cannabis and successfully passed microbial testing required by Health Canada under the ACMPR and will be harvesting its second lot this week so as to conduct full analytical testing, thereby positioning FV Pharma to request a Pre-Sales License Inspection from Health Canada. The Pre-Sales License Inspection is the last step prior to the issuance of a Sales License under the ACMPR.